BioCryst will launch its first oral HAE drug this year
“We are currently in an exciting transformation from a company primarily focused on R&D to one that is about to launch its first oral drug to patients with HAE (ORLADEYO) this year. We expect to end the year with ORLADEYO approved in the U.S. and Japan”, says President and CEO Jon Stonehouse, BioCryst Pharmaceuticals, Inc., … Continue reading BioCryst will launch its first oral HAE drug this year
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed